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Abstract: Epidemiological studies have shown a relation between antioxidants and the 
prevention of several chronic diseases. Microalgae are a potential novel source of bioactive 
molecules, including a wide range of different carotenoids that can be used as nutraceuticals, 
food supplements and novel food products. The objective of this review is (i) to update the 
research that has been carried out on the most known carotenoids produced by marine 
microalgae, including reporting on their high potentialities to produce other less known 
important compounds; (ii) to compile the work that has been done in order to establish some 
relationship between carotenoids and oxidative protection and treatment; (iii) to summarize 
the association of oxidative stress and the various reactive species including free radicals 
with several human diseases; and (iv) to provide evidence of the potential of carotenoids 
from marine microalgae to be used as therapeutics to treat or prevent these oxidative stress-
related diseases. 
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Changes in lifestyle and nutrition, stress most people are submitted to, growing levels of pollution, 
exposure to xenobiotics and radiation that has been increasing for the last decades, and even an excess 
of physical exercise may all be responsible for several metabolic diseases. These factors can cause 
changes in the metabolism, increasing the cellular respiration rate and inducing an imbalance between 
the oxidation products generated and the natural antioxidant capacity of the cells. During the normal 
metabolism, mainly along the respiratory chain in the mitochondria, some free radicals and reactive 
species, either from oxygen (ROS) or nitrogen (RNS), but also proteins and lipids, are naturally elicited 
to suffer (per)oxidation. DNA can be a target as well, leading to genome instability and increasing the 
risk of molecular change and mutations. All these changes may cause damage in the cell metabolism, 
disease and even death. It is known that ROS are associated with a wide range of diseases, such as aging, 
Alzheimer, Parkinson, atherosclerosis, cardiovascular disease (CVD), cancer, inflammatory and 
neurological diseases, diabetes and obesity, amongst others [1–3]. RNS are also involved in the 
peroxidation of lipids and nitration of proteins, as well as in the formation of many other reactive species, 
such as malondialdehyde (MDA), a marker of oxidative stress. 
As with mitochondria, cell organelles that are very vulnerable to oxidative stress due to the high 
concentration of oxygen (O2), the brain and the central nervous system (CNS) are also susceptible to 
lipid/fatty acid peroxidation induced by ROS, because of the high pressures of O2 and oxidation 
reactions. This may be the main reason why neurodegenerative diseases—Alzheimer, Parkinson, 
amyotrophic lateral sclerosis, amongst others—are strictly associated with oxidative damage and/or 
deficiency of endogenous oxidative protection in the cells of the nervous system [4]. Using a simple but 
clarifying scheme, Kalam et al. [4] have synthesized the whole process starting with the formation of 
free radicals, ROS and RNS, and continuing on through the protective responses of antioxidants (AO) 
and the effects of oxidative stress on various macromolecules, which lead to a wide range of chronic 
diseases. Another organ susceptible to being attacked by ROS are the lungs, as they are also exposed to 
a high concentration of O2 and radicals and other reactive species originating from pollutants like 
cigarette smoke, such as O2•− and NO, which trigger oxidative chain reactions [5]. 
However, some of the free radicals and reactive species that result from the cellular metabolism, are 
effective/beneficial in moderate concentrations in regulating the intracellular redox signaling [3], 
fighting the invasion of organisms and inflammation by pathogens [6], or even inducing the cells to 
adapt themselves and protect from other severe oxidative damages. For example, they may create 
tolerance to ischemic-induced conditions [7]. When this equilibrium is broken and reactive species 
surpass the capacity of endogenously-induced anti-oxidative protection of cells, the imbalance induces 
damage by oxidative stress, and regular physiological functions of proteins, lipids, DNA or other 
important biocompounds become impaired, triggering the pathogenesis of several diseases. 
Carotenoids in general, and those from marine microalgae in particular, are excellent antioxidants, 
which can be exogenously supplied to the cells, re-establishing the levels of oxidative stress (OS) and 
nitrogen stress (NS) by neutralizing the excess of free radicals and reactive species. Some of the most 
known and studied carotenoids produced by microalgae include β-carotene from Dunaliella salina, 
astaxanthin from Haematococcus pluvialis, canthaxanthin from Coelastrella striolata, but also the less 
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known, but not less effective, fucoxanthin from several diatoms, such as Phaeodactylum tricornutum, 
and Isochrysis galbana (Table 1). 
Several studies have already been published reporting the association of carotenoids-antioxidant 
properties with protection against several malfunctions and diseases triggered by oxidative stress [8–15], but 
only a few references have dealt with carotenoids from marine microalgae [6,16–21], and even fewer 
studies relate to the beneficial effects of microalgal carotenoids in humans [22–26]. 
This review will focus on the microalgae producing the various carotenoids, their cumulative 
concentrations and the known biosynthesis pathways of carotenoids in microalgae. The antioxidant 
capacity of the different carotenoids against the various radicals and reactive species will also be 
discussed, as well as the benefits of using marine carotenoids (or microalgae biomass) to neutralize the 
oxidative stress, as this may trigger several diseases. 
2. Carotenoids from Marine Microalgae 
Several kinds of carotenoids are produced by marine microalgae (Table 1). Most of them have been 
clearly quantified, but sometimes only the percentage of the total carotenoid yield is known. Many other 
carotenoids have been reported to be constituents of a given microalga, but there in these cases, no 
reference is made regarding their concentration [27,28].  
According to their structure, carotenoids can be classified into different groups. Carotenes (α- and  
β-carotenes (D. salina), and lycopene) do not have any substituent (or even oxygen) in their structure, 
they are strict hydrocarbon carotenoids; xanthophylls or oxycarotenoids present –OH groups 
(hydroxycarotenoids: zeaxanthin from P. cruentum, lutein from C. pyrenoidosa), =O groups 
(ketocarotenoids: canthaxanthin from C. striolata), echinenone from B. braunii, S. platensis), or  
both –OH and =O groups (astaxanthin from H. pluvialis) (Table 1). In addition, some other carotenoids 
have more complex structures, such as violaxanthin (C. ellipsodea) and diadinoxanthin  
(P. tricornutum) with epoxy groups, and dinoxanthin and fucoxanthin (I. galbana) with acetylated 
groups. These last two acetylated carotenoids, which can be found in diatoms, haptophytes and 
dinophytes [29], present the curious structure C=C=C (allene), unique to natural products [30]. A more 
curious structure, acetylene or C≡C, is also part of some carotenoids (all-, diato-, diadino-, hetero-, 
croco-, pyro- and monadoxanthin); these acetylenic carotenoids can be typically found in some groups 
of microalgae, such as the cryptophytes, diatoms, haptophytes, euglenophytes and dinophytes [29]. 
Some new carotenoids have been identified in B. braunii (Table 1). 
Another curiosity is the fact that only two carotenoids have been found in the red marine  
microalga P. cruentum: zeaxanthin (making up 97.4% of the total carotenoids) and β-carotene  
(with only 2.6%) (Table 1). 
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Table 1. Main carotenoids from marine microalgae.  
Main Carotenoid 
Chemical IUPAC Name/ 
Chemical Structure 
Concentration Microalga Other Carotenoids Remarks References 
β-carotene β,β-carotene 10%–13% DW Dunaliella salina 
zeaxanthin, lutein,  
α-carotene 
occur mostly as a mixture of 9-cis and  




50% TC (TC = 0.9% DW) Chlorella zofingiensis 
canthaxanthin (25% TC or 97% DW), 
astaxanthin (0.7% DW) 
 







(as 3S,3′S isomer) 
3,3′-dihydroxy-β, 
β-carotene-4,4′-dione 
up to 7% DW; 75% TC 
Haematococcus 
pluvialis 
β-carotene, lutein, canthaxanthin, 
neoxanthin, violaxanthin,  
zeaxanthin, echinenone 
occur as a racemic mixture of mainly 
mono- and diesters  





0.2%–0.4% DW C. pyrenoidosa 
violaxanthin, loroxanthin,  







astaxanthin 0.15% DW, 







45% TC C. vulgaris 
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1.65%DW P. tricornutum 
diadinoxanthin, eaxanthin, 
neoxanthin, violaxanthin,  
β-carotene 
occur mainly as all-trans  
but also as cis isomers 
[46–48] 




  [50] 
  up to 2.2% DW Odontella aurita diadinoxanthin, β-carotene  [51] 
zeaxanthin β,β-carotene-4,4′-diol 




0.17% DW B. braunii 
botryoxanthins A and B—0.03% 
DW 
braunixanthins 1 and 2—0.06% 
DW 
extracellular pigments are produced and 
secreted into the intercellular matrix 
[53] 
Lutein (intracelular) β,ε-carotene-3,3′-diol up to 0.16% DW  
neox/loroxanthin 0.042% DW 
α- and β-carotene 0.031% DW 










 C. ellipsodea antheraxanthin, zeaxanthin  [45] 
     
TC = total carotenoids. 
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The biosynthesis of isopentenyl pyrophosphate (IPP) may usually be explained by one of  
two different pathways (Figure 1): the mevalonate pathway (MVA) in euglenophytes and  
1-deoxy-D-xylulose-5-phosphate pathway (DOXP) in Chlorophyceae and Cyanophyceae [54,55]. 
Based on Takaichi [29] and Han et al. [27], Figure 1 summarizes the carotenogenesis pathways for 
eukaryotic microalgae, assuming the DOXP pathway for IPP synthesis (Figure 1) and the scheme 
indicated by Takaichi [29] for the pathways in cyanobacteria. Some known genes and the enzymes they 
code for have been isolated from different species of microalgae and cyanobacteria, and their functions 
have been conveniently identified and presented in recent reviews [27,29]. 
 
Figure 1. Pathways for the carotenogenesis and biosynthesis of astaxanthin, based on  
Han et al. [27], Dambek et al. [48] and Takaichi [29], and the synthesis of fucoxanthin and 
diadinoxanthin in diatoms [61], including P. tricornutum, proposed by Dambek and 
colleagues [48]. The genes and enzymes involved in the process and already identified in 
some microalgae are evidenced; the underlined ones were reported by Bertrand [61]. 
MVA pathway         DOXP pathway 




        [54]    IPi, ipi2 
DMAdP 
             ggps 
GGPP 
   [40,48,57]     PSY, psy, psy Pt56881 
phytoene 
     [48,58]     PDS, CrtP, pds, pds Pt45735 
phytofluene 
      [57]     PDS, CrtP 
-carotene 
   [48]     ZDS, CrtQ, zds Pt53794 
neurosporene 
     ZDS, CrtQ 
lycopene 
   [29,48,57,59] LCY-b, lcy-b, lcy-b Pt53794         LCY-e 
-carotene  -carotene 
     LCY-b            LCY-e 
astaxanthin pathways  [27] -carotene    -carotene (-carotene) [60] 
1st pathway      BKT, bkt  CrtR-b      2nd pathway  lutein 
(H. pluvialis)                (C. zofingiensis) 
 echinenone  -cryptoxanthin 
[29]          BKT, bkt         CrtR-b  ZEP   
 canthaxanthin  zeaxanthin            antheraxanthin 
     CrtR-b         BKT, bkt [29]    ZEP, zep 
     adonirubin       adonixanthin   violaxanthin 
 
       CrtR-b   BKT, bkt    neoxanthin 
         astaxanthin 
  (3S,3’S isomer)       diadinoxanthin fucoxanthin [48] 
        DDE 
          diatoxanthin [61] 
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Concerning the derivatives of either β- and α-carotene, most of the steps indicated for the full process 
of the carotenogenesis pathway in algae have been proposed by establishing some relations among the 
chemical structures of carotenoids [29]. However, the real pathways and enzymes involved still need to 
be studied and explained. 
3. Oxidative Stress—The Importance of Reactive Species in Aging and Age-Related Diseases 
Once initiated, the propagation of (per)oxidative reactions, spread out by the reaction of the new 
formed products or free radicals with other chemical species, including peroxyl and alkoxyl radicals, 
which in turn can go on attacking lipids and other biomolecules. For example, peroxynitrite, the product 
of the reaction between superoxide anion radicals and nitric oxide can generate, in the presence of lipid 
hydroperoxides, an oxygen singlet (Figure 2), which is another reactive species (not a free radical) able 
to cause severe modifications in amino acids and/or proteins [62]. 
 
Figure 2. Cascade triggered within a cell by O2•− (superoxide radical) generated mainly by 
NADPH oxidase. Some reactions with lipid hydroperoxides (LOOH) are also included 
(dashed arrows; M = transition metal) [58,63–65]. 
Free radicals are generated during cell metabolism, and their levels may be increased by  
pro-oxidants. They need to receive an electron to pair with the unpaired electron. When these important 
chemical reactive species are overproduced in vivo they can cause an imbalance between ROS and RNS 
and their elimination by the endogenous AO, including enzymes (catalase, for example) and glutathione 
(GSH), which are part of the cell defense mechanisms [4]. The oxidative stress generated will induce 
the chain oxidation reactions, causing cell damage and aging, and, therefore, inducing several diseases, 
including cancer [66,67].  
However, ROS and RNS have addition beneficial effects that are strictly related to cell signaling and 
the immune system, i.e., to supply energy and to get rid of toxins [68], a major role they play when they 
are present in small amounts. When this redox equilibrium is broken, ROS can attack lipids, proteins 
and DNA, forming lipid radicals, amino and thiyl radicals, and sugar- and base-derived radicals that, in 
turn, can be oxidized into peroxyl radicals (Table 2) [4]. Kalam et al. [4] have simply and clearly 
described the (per)oxidation chain reactions starting with the attack of ROS on various essential 
biomolecules, especially lipids, continuing on to the formation of lipid hydroperoxydes and 
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peroxyradicals, and subsequently generating aldehydes. Some of the newly formed radicals can be 
scavenged by the endogenous AO, but others can feed the oxidative chain reaction.  
Table 2. Reactive species causing oxidative stress. 
Groups of Reactive Species Examples 
ROS O2•−, H2O2, HO•, 1O2, O3 
RNS NO•, ONOO•, NO2− 
Lipid hydroperoxides LO•, LOO• 
RCS HOCl, HOBr 
Glycoxidative species AGE, ALE 
Others: Carbonyl radicals, RSS, GS• 
RCS = reactive chlorous/bromous species; RSS = reactive sulfur species; GS• = glutathione thiyl radical. 
Moreover, the reactive aldehydes, such as MDA, hydroxynonenal (4-HNE) and acrolein (ACR), and 
lipid hydroperoxides seem to play a concentration-dependent dual role in the cell metabolism [62]. On 
the one hand, they can show protective functions by acting as signaling molecules and stimulating  
gene expression or neutralizing peroxidative damages by reducing themselves while receiving two 
electrons [62]. On the other hand, as they are highly reactive and toxic, these reactive species may be 
reduced by receiving one electron, initiating the lipid peroxidation cascade [69] and causing considerable 
damage in the cells, sometimes even leading to death [62]. These reactive species can also inhibit gene 
expression, and they play an important role in neurodegenerative diseases. This dual role depends on the 
cellular levels and cell types of the reactive aldehydes: They may present some oxidative protection in 
spite of eventually inducing some cell damage with which cells can survive and subsist, or they may 
cause severe effects leading to the development of several diseases [62]. Compared to free radicals, these 
aldehydes are relatively stable and can be more dangerous than ROS as they can exert their action away 
from the place where they were formed [70], whilst oxygen radicals are short-live species that attack in 
the surroundings of the site of production [71]. Nevertheless, these can also be dangerous. In fact, HO•, 
which is able to start lipid peroxidation close to the site of origin, generating LOO• radicals, is a very 
reactive species [6].  
Ayala and colleagues have recently [62] and extensively given an overview of the relationship 
between oxidative stress and disease; they present simple but clarifying schemes to elucidate the 
mechanisms of lipid peroxidation, especially MDA and 4-HNE formation and metabolism. 
Oxidative stress has also been associated with the formation of atheromas that can lead to 
cardiovascular diseases [3,72,73], including thrombosis after rupture of atherosclerotic plaques. 
Overproduction of free radicals is another feature at the origin of pathological inflammation [3]. By 
using simple schemes, Pashkow [3] has explained the onset of CVD, starting with oxidative stress, which 
greatly interferes with the regular function of platelets. These cell particles release more NO, a reactive 
element that induces an increase of the thrombus due to platelets aggregation. A treatment with a ROS 
scavenger has been suggested to inhibit such platelet behavior, thus stimulating their disaggregation. 
Furthermore, diabetic cardiomyopathy, congestive cardiomyopathy and hypertension-related heart 
disease were some of the diabetic complications arising from oxidative stress that were given in the 
overview by Pashkow [3]. 
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Klaunig et al. [74] are another group that worked on the link between oxidative damage and disease, 
namely carcinogenesis. They suggested that the increase in number and size of peroxisomes (cell organelles), 
which are induced by hypolipidemic drugs and other substances, may be associated to liver cancer [75]. 
This may be explained by an increase of the peroxisomal enzymes acyl-CoA and xanthine oxidase (XO) 
induced by oxidative stress that enhances the production of ROS, such as H2O2 and O2•−. 
Another reason for the association of oxidative stress with disease is the fact that F2 Isoprostanes  
(e.g., 8-iso-PGF2α) are biomarkers associated with lipid peroxidation. They are indicators of the presence 
of diabetes 1 and 2 in the urine [76]. The formation of these substances and the subsequent increase of 
thiobarbituric acid reactive species (TBARS) (Table 3) can be inhibited by the endogenous superoxide 
dismutase (SOD) and butylated hydroxy-toluene (BHT) [77]. Perhaps, a similar response might  
be obtained by using carotenoids, as they, or at least some of them, are able to neutralize oxygen  
free radicals (Table 4). Moreover, oxidative stress has been associated with hyperglycemia for  
decades [73,78,79]. Mezzetti and colleagues [76] have concisely established various links between the 
different sources of oxidative stress and the associated biomarkers (Table 3), which also appear in higher 
levels in plasma and/or urine of diabetics and patients with related complications, such as atherosclerosis. 
Additionally, in diabetics for example, the autoxidation of sugars, plasma unsaturated lipids and 
proteins from cell membranes, and the reactions between sugars and proteins produce free radicals, 
which may be the cause of oxidative stress and damage. Baynes [8] established some relationships 
between oxidative stress and the subsequent effects/damages in diabetic patients. He described some 
sources of oxidative stress, and suggested some therapeutical treatments using antioxidants and  
anti-inflammatory agents, other than carotenoids, to reduce the effects of oxidized lipoproteins and lipid 
peroxides. These relationships may explain the (per)oxidative and inflammatory processes as triggering 
the initial steps of diabetes, but also complications derived from the development of the disease itself. 
This type of therapeutics can be used to break down the chain-production of free radicals [8] as well. 
Baynes [8] also reviewed the reactions that may lead to atherosclerosis, as a complication generated by 
the oxidation of lipids and lipoproteins in diabetics. Some biomarkers for oxidative stress (Table 3) in 
these patients were given as well, as some of those glycative and/oxidative products (Table 3) are unique 
and stable. 
In addition, one of the theories on aging claims that it might result from damaged tissues caused by 
reactive species, such as free radicals that are generated during the consumption of oxygen by 
mitochondria. During aerobic respiration, the agents responsible for the AO defense are overwhelmed 
by these ROS and an imbalance is created. By using the right natural carotenoids, including those from 
marine microalgae, at the corrected doses, the levels of such reducing agents would be expected to 
improve, restoring the endogenous antioxidative system in the cells [80]. 
Furthermore, according to Kalam and co-workers [4], it seems that the initiation process in chronic 
diseases is always associated with the overproduction of reactive species (e.g., ROS), which mediate the 
initial steps of inflammation that leads to carcinogenesis, directly by the oxidation, nitration or 
halogenation of lipids or nucleic acids, or indirectly by activating the signaling pathways. 
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Table 3. Main biomarkers of oxidative stress. 
Biomarkers Remarks References 
MDA 
reactive aldehyde; lipid peroxidation of  
ω-3 and ω-6 FA 
[81] 
4-HNE 
reactive aldehyde; lipid peroxidation of  
ω-3 and ω-6 FA 
[81] 
acrolein reactive carbonyl [5] 
LOOH lipid hydroperoxides [82] 
Glycoxidation products: carbonyl-derived from protein changes 
[8,76,83] 
pentosidine (AGE) marker for diabetes-associated complications 
Nε-(carboxymethyl)lysine (AGE) (CML); marker for diabetes-associated complications 
Nε-(carboxymethyl)hydroxylysine (CMhL) (AGE) 
o-, m-, and dityrosine  
fructoselysine marker for diabetes 
fructosehydroxylysine  
ketoimine and ketoamine adducts to protein 





Cell apoptosis markers (hallmarkers): 
DNA fragmentation 
condensation of cell nuclei 
 
[86] 
PARP breaking poly ADP ribose polymerase 














isoprostanes (e.g., IPF2α-I) 
useful for atherosclerosis plaques; markers for lipid 
peroxidation in vivo 
LOOH & thiobarbituric acid reactive 
species (TBARS) 
 
enediol radical anion 
marker for diabetic patients; results from autoxidation 
of glucose 
* useful for DNA lesions and human cancers. 
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4. Carotenoids from Marine Microalgae against Oxidative Stress 
4.1. Uptake and Bioavailability 
Most carotenoids cross the cell membrane by simple or facilitated diffusion [92–95] and are delivered 
through the body as a part of lipoproteins [93–97]. All-trans and 9-cis forms of β-carotene are mainly 
accumulated in chylomicrons and VLDL, respectively [98], and xanthophylls in LDL and HDL [99,100]. 
However, astaxanthin appears mostly in VLDL-containing chylomicrons [101], and lutein and 
zeaxanthin are found to be preferably absorbed into chylomicrons [102]. 
According to several groups of researchers, carotenoids are better available if administered along 
with some kinds of fat, such as phospholipids or special edible oils [26,92,103,104] as the vehicle, since 
carotenoids are better absorbed into chylomicrons at the intestine level. From here they are delivered to 
the cells of the individuals/animal models, where they seem to be especially integrated into the 
mitochondria [86,96,105], but also into nuclei and microsomes [96]. However, different carotenoids 
seem to be absorbed differently. For example, fucoxanthin has been found to being better absorbed than 
lutein or astaxanthin, the metabolites of these being found in higher concentrations in mice [106,107]. 
Furthermore, these metabolites, fucoxanthinol, amarouciaxanthin A and halocynthiaxanthin, have 
already been identified in several animal models and cell-lines [108–111]. Some studies have even 
suggested a better bioavailability of fucoxanthinol than fucoxanthin [112], and have reported that the 
former is converted into amarouciaxanthin A in the liver [103]. Additionally, no fucoxanthin has been 
found in the liver and plasma [110,113], but fucoxanthinol and amarouciaxanthin have been detected in 
several tissues [107]. More recently, Rao and co-workers [114] found that astaxanthin, β-carotene and 
lutein from different microalgae appeared mainly in the liver, with astaxanthin being preferentially 
absorbed; this carotenoid also showed a higher AO capacity by increasing catalase, SOD and peroxidase 
to higher levels and by preventing in vivo lipid peroxidation. Additionally, astaxanthin demonstrated to 
be better available and accumulated in larger amounts than lutein and β-carotene in a rat-model. It is 
worth noting though that in this study [114], the results among different groups of animals could have 
been influenced by other compounds of the microalgal biomass, since the various carotenoids were 
administered as being part of referred biomass from H. pluvialis, S. platensis and B. braunii. In addition, 
natural carotenoids already have been shown to be better available than synthetic ones [115], and the 
availability is also improved if carotenoids are taken after meals [116]. Furthermore, Régnier et al. [21] 
found that a natural racemic mixture of astaxanthin extracted with solvents presented twice as much 
antioxidative protection as that extracted by supercritical methods; this protection was almost five times 
higher (in vitro tests) than that of synthetic astaxanthin, which presented even lower activity than 
astaxanthin obtained by supercritical methods. However, when AO activity of various extracts were 
tested in Human Umbilical Vein Endothelial Cells (HUVEC) cells, the antioxidative cell protection was 
almost 90 times higher with the natural astaxanthin containing esters than with the synthetic  
xanthophyll [21], thus contributing to the cells’ defense against oxidative stress. Regarding astaxanthin, 
the geometrical isomer 3S,3′S was more readily absorbed despite being in a lower concentration in a 
racemic mixture, and cis (Z) forms were selectively absorbed [117], especially 13Z isomers [101]. 
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4.2. Antioxidant Protection 
In the near future, unicellular microalgae might be an alternative source to obtain AO because their 
carotenoids (Table 4), phenolics and other bioactive compounds, such as vitamins, fatty acids and 
polysaccharides, act synergistically towards their AO properties, which may be of some usefulness 
against oxidative damage [118]. 
Table 4. Antioxidant activity of main carotenoids from microalgae against reactive species. 
Carotenoid AO activity Reactive Species References 
astaxanthin 
1O2 quencher, 1O2, 
[6,86,119–123] 
radical scavenging, O2•−, H2O2, HO•, 
ROS and RNS quencher, NO, LOOH, ONOO−, HOCl 
chain-breaking AO, 




1O2 quencher; 1O2, 
[6,124–126] 
radical scavenger; NO2, ONOOH and ONOO− 
inhibits Na+K+-ATPase,  
stimulates catalase and GS transferase 
 
canthaxanthin 




1O2 quencher, 1O2, 
[6,103,124,127–133] 
radical scavenger; O2•−, HO•,ONOO−, HOCl, 
inhibits Na+K+-ATPase, stimulates catalase 
and glutathione transferase 
DPPH•, 12-DS•, NB•-L, AAPH, 
ABTS, ABAP, AIBN 
There is evidence that a diet rich in carotenoids and other bioactive compounds protects from several 
diseases, including obesity and cancer; oxidative stress is known to be associated with those diseases 
and malfunctions; hence, carotenoids might inhibit the onset of these diseases due to their AO activity. 
It is also known that carotenoids exhibit their antioxidative properties by being good scavengers of 
several chemical radicals and potent quenchers of singlet oxygen (Table 4). 
In order to deactivate reactive species and stop oxidative reactions, AO (vitamin C, thiol, fucoxanthin, 
polyphenols) usually donate electrons, but some can also be proton donors, as happens with fucoxanthin, 
GSH and α-tocopherol [132]. Some of them act as “real” cellular AO (GSH), some others are chain-
breaking AO as they can stop oxidative reactions, such as α-tocopherol [134]. 
The unique molecular structures of some carotenoids, which have additional oxygenic functional 
groups (epoxy, hydroxyl, carbonyl and/or carboxyl), together (or not) with special unique allenic features 
(Table 1) and several conjugated double bonds, provide them with a strong AO activity, as happens with 
fucoxanthin [124]. Algal fucoxanthin has already demonstrated to effectively protect from ROS and 
oxidative-induced damages [135], with the AO activity being higher than that of α-tocopherol. Rodrigues 
and colleagues [6] also found that fucoxanthin was one of the strongest carotenoids scavenging HOCl, 
only surpassed by astaxanthin. However, in another study, β-carotene showed to be better a 1O2  
quencher [124], and halocyanthiaxanthin was the best suppressor of O2•− among about twenty 
carotenoids, despite demonstrating the lowest scavenging properties [136]. In contrast, Pashkow and 
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colleagues [137] describe that astaxanthin has the highest AO capacity among several carotenoids, 
including β-carotene, zeaxanthin and canthaxanthin, with it being 500-fold higher than that of vitamin E 
as a 1O2 quencher [138], and 100 times greater than that of α-tocopherol with respect to the protective 
effects against lipid peroxidation [139]. The AO activity of astaxanthin as a scavenger of various reactive 
species (LOO•, HOCl and ONOO−) was also demonstrated by Rodrigues’ group [6]. It was even more 
potent than α-tocopherol. Regarding RNS. However, scarce information is available concerning the capacity 
of carotenoids to scavenge other radicals, such as ONOO−. However, Rodrigues and co-workers [6] found 
that β-carotene was the best ONOO− scavenger among several carotenoids. Also, carotenoids with 
oxygenic substituents, especially –OH, which can easily donate protons, showed to be better than the 
hydrophobic carotenes at neutralizing ROS. This dependency on the amounts of oxygen of carotenoids 
influencing the sensitivity to radicals and their AO was observed by other researchers as well [132,138], 
with the AO activity usually being inversely correlated with oxygen tension [125]. 
Despite the lower concentration in carotenoids, mainly astaxanthin, their extraction from palmeloid 
cells of H. pluvialis is easier and their content is more readily available. This is a positive aspect when 
whole cells are administered to produce antioxidative properties of their carotenoids. Owing to the 
absence of a hard cell wall, these reddish palmeloid cells are more suitable for human consumption [42]. 
In certain conditions, when the content in astaxanthin is lower, the fatty acid (FA) content may also play 
a role in the AO capacity [118] of H. pluvialis, perhaps because astaxanthin is present mainly as mono- 
and diesters, especially with oleic acid. According to Cerón et al. [42], the AO power of astaxanthin in 
vitro against the radical DPPH is 10 times higher than that of β-carotene, 500 times higher than that of 
α-tocopherol, and diesters are 1.6 times more potent than monoesters and twice as potent as free 
astaxanthin. In addition to the AO potential, astaxanthin is also an antiglycant [28]. Therefore, this 
carotenoid is able to protect from glycation of proteins, which may be subsequently oxidized to form 
glycoxidation products (Table 3). However, protein oxidation products can have a positive oxidative 
stress response as well. S-nitrosylation of a single cysteine residue and S-sulphenation of cysteine, where 
sulphydryl group of cysteine is converted to a S-sulphenation product, or addition of a group –SOH to 
DJ-1 protein is related to Parkinson’s disease; this oxidation product has a positive effect and is neuron 
protective [7]. 
Additional protection in cells may come from the beneficial activity of some ROS that can interact 
with NO to form peroxynitrite (Figure 2), which in turn can react with carotenoids to form 
nitrocarotenoids that scavenge those radicals. However, few reports exist on this matter [123,129]. 
Peroxynitrite, a reactive nitrogen species, is responsible for the nitration of tyrosine, as a free aminoacid 
or as a monomer in proteins, and for the oxidation of LDL, peroxidation of lipids and fragmentation of 
DNA [140]. Fucoxanthin inhibits nitration of tyrosine by reacting with peroxynitrine and forming  
Z-nitrofucoxanthin [129], thus, proving the capacity to neutralize those radicals. These new products 
also showed to have anti-tumor and anti-proliferative properties, which are induced/triggered by RNS.  
This anti-carcinogenic activity of nitrofucoxanthin has even been found to be higher than that of 
fucoxanthin [129]. Astaxanthin and lutein can also scavenge RNS ONOO• to form 15Z-nitroastaxanthin 
and 15Z-nitrolutein that, besides maintaining antioxidative activity against oxygen singlet and inhibiting 
nitration of tyrosine, has shown (as it happens with nitrofucoxanthin [129]) anti-tumorigenic-induced 
RNS properties higher than those of astaxanthin and lutein [123]. However, astaxanthin demonstrated 
an AO activity as a 1O2 quencher higher than nitroastaxanthin, and even higher than β-carotene; lutein 
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and nitrolutein have similar 1O2 quenching activities, higher than β-carotene [123]. Astaxanthin showed no 
cytotoxicity for several kinds of cell-lines, either healthy or tumor cells, when in doses up to 16.75 μM [21]. 
Additionally, no side effects were noticed in the studies reported and reviewed by Fassett and Coombes [13]. 
In what concerns fucoxanthin, in addition to its high AO activity, this unique carotenoid is also able 
to modulate certain genes involved in the cell metabolism [141], and these properties seem to be essential 
for health. However, fucoxanthin metabolites, fucoxanthinol and amarouciaxanthin A, seem to be 
responsible for the physiological effects in the gastrointestinal tract and liver, respectively, in mice and 
rats [107,109,142], and the conversion from fucoxanthin into its metabolites has been observed in Caco-2 
and HepG2 human cell-lines as well [92,109,110]. Nevertheless, as drugs in general have a shorter 
retention time in smaller animals [143], the effects of bioactive compounds, such as fucoxanthin and the 
respective metabolites, cannot be directly compared with the correspondent in humans, where 
bioavailability is higher due to a slower metabolism. In addition, absorption of fucoxanthin, and perhaps 
other carotenoids, depends on the food ingested, since its solubility is low in vitamin E and some 
vegetable oils, but is rather dissolved in medium-sized triacylglycerols and fish oil [144,145]. 
Furthermore, as it happens with β-carotene, the chemically synthesized fucoxanthin might not 
demonstrate the same functionalities as those from the natural racemic cis-trans mixtures. Regarding 
safety, fucoxanthin has proven to be a safe product in several studies with different cell-lines and animal 
models, either administered in one single dose or given over a period of time [146,147], as reported by 
Peng et al. [103]. Fucoxanthin from marine algae has also proven to be able to regulate lipidemic marker 
levels in the blood and liver of various (obese) animal models and reduce their white adipose tissue and 
body weight as well [148–153]. A decrease of body weight, body and liver fat in obese women treated 
with Xanthigen, some of them with non-alcoholic fatty liver disease (NAFLD), was also observed in a 
clinical study carried out by Abidov and coworkers [26]. In this study, an increase of energy dissipation, 
perhaps by thermogenesis, was verified as well in those treated women. Additionally, this xanthophyll 
carotenoid was also shown to regulate mRNA expression of several cell events and activity of various 
enzymes [150,153], including lipase activity at the intestinal level [154]. Gammone and D’Orazio [153] 
and Peng’s group [103] focused on the mechanisms of fucoxanthin and its metabolites as powerful 
agents against obesity. However in most studies, fucoxanthin was not obtained from marine microalgae, 
but from brown seaweeds. The main mechanism that explains the anti-obesity properties of fucoxanthin 
and its metabolites seems to be associated to its capacity to stimulate uncoupling proteins  
(UCPs) [153,155,156]. UCP-1 (thermogenin), for example, induces fatty acid oxidation and also inhibits 
oxidative phosphorylation at the mitochondria level, thus enhancing the burning of excess calories, 
which are dissipated off (energy expenditure) from the body in the form of heat (thermogenesis) [153]. 
Moreover, different carotenoids, carotenes or xantophylls with different optical (cis, trans, racemic 
mixtures) or geometrical (R/S) forms may present different behaviors at the cell membrane level: they 
can change the membrane permeability and fluidity, as they can cross along the entire membrane (as is 
the case for astaxanthin and zeaxanthin) or not (as it is likely for β-carotene and lycopene); this may 
interfere with their capacity to intercept/react with reactive species/toxins [157]. This could be an 
explanation for the low ability of β-carotene to inhibit peroxidation of hydrosoluble peroxyradicals, 
whereas zeaxanthin and astaxanthin are more able to do so [158]. Additionally, various carotenoids may 
co-exist in animal and human tissues and, therefore, the effect may be synergistic among those lipophilic 
carotenoids, such as β-carotene and lycopene (acting within the hydrophobic bilayer of cell membranes) 
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and xanthophyll carotenoids that have polar and non-polar regions, such as astaxanthin and zeaxanthin, 
which can cross the membrane. This explains why a mixture of carotenoids with different chemical 
characteristics should be administered to prevent oxidative damage and related diseases. Also, the use 
of the microalgal biomass of a mixture of different genera, such as Spirulina platensis, H. pluvialis and 
Dunaliella salina could be suggested. 
4.3. Role of Carotenoids against Reactive Species and Diseases 
Liu and co-workers [86] have untangled the link between oxidative stress-generated cell damages in 
Parkinson’s neurodegenerative disease (PD) and the treatment with the xanthophyll carotenoid 
astaxanthin. With concentrations as low as 100 nM, astaxanthin demonstrated its AO potential to protect 
mitochondria of dopaminergic cells, inhibiting peroxidation of lipids, which are severely neurotoxic to 
the cells, therefore preserving loss of dopaminergic neurons and protecting from PD’s evolution. The 
protective effect was dose-dependent and associated to the fact that astaxanthin was preferentially 
accumulated in mitochondria [86]. Furthermore, the oxidative protection of the brain and the 
neuroprotective effect of astaxanthin may also be due to the fact that this carotenoid can cross the  
blood-brain barrier as it has been observed in rats’ brain tissue, patented by Tso and Lam in 1996 [159], 
and in other experimental animals [160]. Astaxanthin also reduced biomarkers 8-OHdG and  
4-HNE (Table 3) presented in high levels in cardiac and skeletal muscles of rats, because of the oxidative 
stress induced by excessive physical exercise [87]. Athletes are particularly affected by oxidative stress 
due to the high physical efforts, which cause an overproduction of ROS [155]. Thus, an alternative 
prevention against oxidative stress and the subsequent weakness of the immune system and 
inflammatory conditions might arise from the intake of carotenoids from marine microalgae, especially 
astaxanthin and fucoxanthin, two powerful antioxidant carotenoids. In addition, fucoxanthin might be 
useful, as this marine xanthophyll carotenoid seems to enhance thermogenesis by improving UCPs gene 
expression and protein activity, decreasing the athlete’s body weight, and therefore improving body 
performance during sports [155]. In addition to astaxanthin from H. pluvialis and fucoxanthin from  
O. aurita and P. tricornutum [161,162], other carotenoids that can be obtained from various marine 
microalgae have already been demonstrated to have a wide range of health benefits. This is the case of 
violaxanthin from C. ellipsodea [45,163], canthaxanthin from C. vulgaris and C. striolata var. 
multistriata [37,44]. 
5. Why Is There Limited Success of Carotenoids as Anti-Oxidant Agents in  
Studies/Clinical Trials? 
Some researchers have pointed out a wide range of reasons for the failure of carotenoids as AO in 
tests and clinical trials [3,96,125,164]. The controversial results for the AO properties of carotenoids 
may possibly be related to an inappropriate choice of the tests for the oxidation products and the 
biomarkers used, the targeted tissues and the features within the cell. Also the design of the 
experiment/clinical trial in what concerns the origin and concentration of the right carotenoid, their 
mechanisms of action and the way of administration, the dose, the duration of the study/therapy, the 
model/system chosen and the biomarkers selected for the study may have a great influence on the results 
obtained. Another question has to be asked: are these double-blind placebo-controlled and  
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long-term clinical studies/trials with statistically relevant numbers of individuals? In 2011, Fassett and 
Coombes [13] referred to the non-existence of such clinical trials, at least for CVD treatment/prevention 
using astaxanthin. 
Following this reasoning, the design of such studies/trials should take into account the chemical and 
structural characteristics of the various carotenoids, naturally produced vs. synthetic, their isomeric and 
geometric structures, their polarity and redox potential and the pattern of responses elicited in different 
oxygen pressures in order to choose the most sensitive biomarkers. The probability of the various 
carotenoids to interact and/or be synergistic with other carotenoids and/or other AO during the metabolic 
reactions in the whole individual should also be considered. The model should be carefully selected 
since the human absorption, metabolism and bioavailability of carotenoids is different from other 
animals, and the chosen animal, as a whole system, implies the existence of different needs, enzymes 
and responses to different carotenoids. Therefore, the effects at the level of the tissues and/or organs are 
different from those obtained in chemical tests or even in cell lines, where different responses may be 
triggered. The best animal models seem to be gerbils, ferrets and calves, as they seem to use and 
metabolize carotenoids in a similar way as humans [96]. 
It is worth noting though that when the immune system is deficient, leukocytes cannot produce 
enough superoxide anion or NO and, thus, a pro-oxidant therapy should be required. Therefore, a 
carotenoid treatment might be useful in order to trigger this pro-oxidant reaction. The doses administered 
depend most of the time, if not always, on the chosen carotenoid. Fucoxanthin, for example, has already 
been demonstrated to exert an AO activity by starting some pro-oxidant effects [128]. Responses 
obtained also depend on the duration of the study/treatment. Furthermore, β-carotene and other 
carotenoids can lose their AO properties and act as pro-oxidants when in high concentrations [164–166] 
and in the presence of oxygen [125]. This may also be related with the carotenoid aggregation. Burton 
and Ingold [125] decribe that, under high oxygen pressures, some carotenoids can suffer auto-oxidation, 
which may explain the reduction of their AO effectiveness. 
Moreover, the AO/pro-oxidant activity of carotenoids strongly depends on the oxygen (O2) pressure, 
and it has to be considered that, except for the lungs and brain, tissues are normally subjected to low O2 
pressures. Furthermore, β-carotene has demonstrated a better radical scavenging activity under low 
concentrations of O2 [125], whilst fucoxanthin is better in anoxic conditions, probably due to the oxygen 
substituents in the chemical structure [132]; however, in another study, fucoxanthin was less active than 
α-tocopherol under high oxygen pressures [167]. 
Additionally, Sangeetha’s group [20,113] demonstrated a higher protection against lipid peroxidation 
of fucoxanthin when compared to β-carotene, with respect to the increase of the activity of catalase and 
glutathione (GS) transferase and modulation of Na+K+-ATPase (Table 4), thus restraining lipid 
peroxidative stress. These two carotenoids also showed a singlet oxygen quenching ability by inhibiting 
oxidation of vitamin D [168]. 
The biochemistry of carotenoids, the way they act, the mechanisms of their interaction with other AO 
and with different reactive species, the products that result from these reactions and the dual character, 
either as AO or as pro-oxidants, of carotenoids were summarized by El-Agamey and colleagues [157]. 
One reason for the pro-oxidant reactions of carotenoids given by these researchers is the depletion of 
AO, such as vitamins C and E, which may result in the formation of carotenoid radicals that can function 
as oxidizing agents [157]. They also describe that carotenoids may exert their scavenging activity either 
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by donating electrons or protons, or by forming adducts with the radicals, depending on their lipophilic 
or hydrophilic nature. Each type of mechanism may depend on the polarity of the carotenoid as well as 
on the reactivity of the radicals. 
The benefits of carotenoids also depend on their molecular structure: carotene carotenoids  
(β-carotene, lycopene) can only (inter)act within the lipid bilayer of membranes as they do not have 
polar endings like xanthophyll carotenoids astaxanthin, canthaxanthin and fucoxanthin. This may 
explain, at least partially, why some carotenoids preserve the membrane integrity better [169] and  
have protective effects [14], and others may even cause lipid peroxidation and damage in cell  
membranes [169,170], demonstrating a pro-oxidant potential, when normally administered in high  
doses [125]. 
6. Conclusions/Final Remarks 
Several epidemiologic studies have shown that diets rich in antioxidants reduce the risk of developing 
several chronic inflammatory diseases, such as Parkinson, diabetes, cancer and CVD. Carotenoids 
represent the most abundant lipid-soluble phytochemicals, and in vitro and in vivo studies have suggested 
that they have a large range of biological properties, such as, antioxidant, anti-inflammatory, modulation 
of gene expression and many others.  
Microalgae are a potential novel source of bioactive molecules, including a wide range of different 
carotenoids. Several carotenoids from marine microalgae have been associated with beneficial health 
effects. These natural compounds have being used as nutraceuticals and food supplements, although the 
biomass itself may also be incorporated in novel functional food products. By consuming naturally 
produced carotenoids from microalgae and the biomass in the diets, along with a healthy way of living, 
with moderate exercise and a decrease of exposure to oxidative agents, humans’ health may improve. 
This would increase the endogenous antioxidative protection and even prevent some harmful 
mechanisms and repair damages in the cell and the whole organism. Several pathways involved in the 
bioactivity of carotenoids have already been disclosed. However, research is still required on the  
dose-response relations of carotenoids, their metabolites and their effect on the human metabolism. 
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